Here’s why Moderna is surging (January 6)

Traders Union
All News
Financial News
Moderna Surges 6.85% to $34.38 Today

Highlights

Moderna reaffirmed its 2025 revenue guidance, projecting $1.6 billion to $2.0 billion, as it advances its seasonal vaccine portfolio and COVID-19 products.
The company submitted regulatory filings for its investigational mRNA-1010 influenza vaccine in several major markets, following positive Phase 3 trial results in older adults.
Moderna is progressing with its oncology and rare disease pipelines and remains under ongoing FDA review regarding COVID-19 vaccine safety, confirming its current strategic focus.

Revenue guidance and positive trial data drive sentiment and strategic clarity

Moderna reaffirmed its 2025 revenue guidance, projecting $1.6 billion to $2.0 billion, as it continues advancing its seasonal vaccine portfolio and COVID-19 products. The company has submitted regulatory filings for its investigational mRNA-1010 influenza vaccine in several major markets, supported by positive Phase 3 trial results in older adult populations. Additionally, Moderna is moving forward with its oncology and rare disease pipelines, and is under ongoing FDA review regarding COVID-19 vaccine safety, while confirming its current strategic focus in a recent shareholder letter.

Anton Kharitonov, expert at Traders Union, notes that Moderna's price surge is notable but raises risk flags. He points out the overbought conditions across multiple oscillators. Kharitonov highlights that strong news flow and positive trial results drive sentiment but warns that current valuations could be stretched. Regulatory reviews introduce downside risk if any negative findings emerge. He says, "Momentum may sustain short-term rallies, but I remain cautious until support at $29.91 is thoroughly tested."

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s reaffirmed revenue guidance and pipeline progress as clear positives. He sees strong performance in mRNA vaccines and global regulatory submissions as foundational for future growth. Karapetjanc believes the bullish structure remains intact, with robust momentum driving the price action. He states, "With multiple revenue streams and strong demand signals, I expect further growth as Moderna leverages its innovative portfolio."

Overbought signals and strong momentum boost, but volatility tests near-term support

The current price of $34.38 is well above the MA-20 at $30.62, the MA-50 at $27.30, and the MA-200 at $27.38, signaling that the short-, medium-, and long-term trends are firmly bullish. The price is also significantly above the Ichimoku Kijun at $29.91, which now acts as dynamic support, while the next key resistance may be found near the previous local highs or round levels above $35.

Momentum signals remain strong, with the MACD showing a strong buy and the ADX confirming a bullish trend. Daily RSI and CCI both indicate renewed buying interest, though overbought readings on the Stochastic RSI, CCI, and BBP suggest some intraday froth, with buyers currently dominating the session. The Awesome Oscillator is neutral, while daily direction is up, with the price rising 6.85% after opening with a minor upward gap from the previous close; the current price sits near today's high, showing high intraday volatility and sustained strength toward the session highs. Some divergence between overbought oscillators and strong momentum highlights risk of near-term pullbacks, but today's rally is well-supported by underlying momentum.

Last time, analysts noted that Moderna was maintaining strong momentum relative to all major moving averages, with bullish signals from MACD and ADX supporting upward movement while RSI showed modest optimism and Stoch RSI indicated an oversold condition. Technical divergences were present but intraday action favored continued strength toward session highs, driven by buyer dominance as evidenced by the upper end of today’s range and moderate volatility.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.